Chukwunonso Nwabufo named chair of Pharmacokinetic, Pharmacodynamic, and Drug Metabolism community of the American Association of Pharmaceutical Scientists
Chukwunonso Nwabufo, a PhD candidate and CIHR Scholar at the Leslie Dan Faculty of Pharmacy, has been appointed chair of the American Association of Pharmaceutical Scientists’ (AAPS) Pharmacokinetic, Pharmacodynamic, and Drug Metabolism (PPDM) community.
As chair, Nwabufo will develop community goals and programming strategy, lead community recruitment initiatives, increase membership, foster networking, and educational growth opportunities for members to support AAPS’s vision of advancing the pharmaceutical sciences to drive prevention and cures.
A significant recognition in the pharmaceutical sciences, Nwabufo was appointed chair in October 2023. He has officially taken on the year-long role.
“It is both an honour and a privilege to lead a community of more than 1,200 outstanding scientists from renowned academic and pharmaceutical institutions,” Nwabufo says.
AAPS is a globally recognized organization with more than 7,000 members and 10,000 stakeholders from academia, industry, government, and research institutes. They are dedicated to advancing pharmaceutical science and positively impacting global health.
Meanwhile, the PPDM community, with more than 1,200 members, specifically focuses on preclinical and clinical drug development, and provides scientific and career development outreach. This community serves as a hub for pharmaceutical scientists from academia, industry, and government to collaborate and advance their knowledge and expertise in the field.
Nwabufo’s top priorities for his tenure is to encourage innovative approaches in PPDM, strive for excellence by consistently achieving top-tier standards, and to foster inspiration by nurturing the next generation of leaders in the field.
“I look forward to collaborating with our community members to innovate, excel, and inspire the next generation of leaders in pharmaceutical sciences, thereby making substantial contributions to AAPS, and the advancement of drug development for unmet medical needs,” Nwabufo says.
In November 2024, Nwabufo will begin his role as immediate past chair of the PPDM community. The role of the past chair is to serve as a mentor and resource for the current chair, ensuring the continuation of ongoing projects, coordinating community programming, and representing the community as needed.
Nwabufo is the founder and CEO of OneDrug, an innovative biotechnology start-up making healthcare more personalized by empowering doctors with technologies to rapidly identify patients at risk of adverse drug effects.
Recent News
